• Explore /
  • Poster
  • / A phase II trial of [fam-] trastuzumab deruxtecan (T-DXd, DS-8201a) in subjects with HER2-positive, unresectable, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

A phase II trial of [fam-] trastuzumab deruxtecan (T-DXd, DS-8201a) in subjects with HER2-positive, unresectable, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Abstract Poster

Authors

null

Charles S. Fuchs

Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT

Charles S. Fuchs , Javad Shahidi , Lijoy Mathew , Amy Qin , Eric Van Cutsem

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04014075

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr TPS460)

Abstract #

TPS460

Poster Bd #

L4

Abstract Disclosures

Similar Posters

First Author: Jin Li

First Author: Timothy Jay Price

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Clinicopathological features of HER2-low expressed advanced gastric cancers.

Clinicopathological features of HER2-low expressed advanced gastric cancers.

First Author: Izuma Nakayama

First Author: Yelena Y. Janjigian